遠隔患者モニタリング2023-2033年: 技術、市場、機会: IDTechEx

遠隔患者モニタリングを支援するメドテック機器市場が2033年までに450億米ドルに成長する見通し

遠隔患者モニタリング2023-2033年: 技術、市場、機会

動作、心拍数、血圧、心拍リズム、血糖値などの患者遠隔モニタリングのウェアラブル機器やコネクテッド医療機器の利用に関するトレンド、ビジネスチャンスおよび市場予測


製品情報 概要 目次 価格 Related Content
遠隔患者モニタリング(RPM)とは、従来の医療環境を超えて生理学的データを測定・送信する技術のことで、新型コロナウイルスの感染拡大以来注目されるようになりました。IDTechExはこのレポートで血圧計カフ、24時間心臓モニターなどのコネクテッド医療機器や心疾病、糖尿病、呼吸器や全般的な健康とウェルネスにおけるRPM用途の持続血糖測定機器を網羅しています。2033年までの10年先の市場見通しは19種の製品カテゴリーを対象としています。
「遠隔患者モニタリング2023-2033年 」が対象とする主なコンテンツ
(詳細は目次のページでご確認ください):
• 全体概要および結論
• 遠隔患者モニタリング市場の主要原動力とトレンド
• 遠隔患者モニタリング企業の概要
• 遠隔患者モニタリング技術(疾病分野別/用途別)
□ 入院患者と外来患者を対象とするバイタルサインのモニタリング
□ 高血圧、不整脈や心不全患者が利用する技術を含む心疾病
□ 血糖値測定とインスリン投与を含む糖尿病
□ スマート吸入器を含む呼吸器疾患
□ RPMが対象とするその他の慢性疾患
□ 臨床試験
□ 高齢者モニタリング
□ ウェルネス
• 19種の遠隔患者モニタリング製品ライン/カテゴリーにまたがる10年先の市場見通し
• インタビューを含む63社の企業概要
 
「遠隔患者モニタリング2023-2033年」は以下の情報を提供します
  • 主な企業や業界の原動力を含む遠隔患者モニタリング業界の概要
  • 主な慢性疾患用途を含む技術やトレンドの分析
o 患者の快適さの増進と病棟へのモニタリング導入
o 高血圧とカスレス血圧計の開発
o 不整脈とウェアラブル機器の台頭
o 糖尿病と持続血糖測定に向けた動き
o 運動障害におけるウェアラブル機器のビジネスチャンス
o 高齢者のモニタリング
o デジタルバイオマーカーと分散型臨床試験
o 医療保険とウェアラブル技術向けのインセンティブ
  • 19種の製品/製品カテゴリーにまたがる慢性疾患患者の遠隔モニタリング向けコネクテッド医療機器に関する10年先の市場見通し
 
As healthcare spending around the world increases, innovative methods of delivering cost-effective healthcare must be developed. Remote patient monitoring (RPM), referring to the use of technology to measure and transmit physiologic data beyond traditional healthcare settings, has emerged as a promising solution to drive down healthcare costs while maintaining a high standard of care for patients. The importance and value of RPM has been emphasized by the need to keep patients out of hospitals and clinics during the COVID-19 pandemic, which has in turn accelerated adoption of RPM.
 
 
Source IDTechEx
 
Overall, RPM technologies and services enable healthcare providers to care for their patients outside of their regularly scheduled visits, following a global trend in decentralization to alleviate overburdened hospitals and clinics. For patients, RPM not only allows for the elimination of costly and time-consuming travel, but also increases quality of life, reduces hospitalizations and emergency room visits, and reduces hospital stay times. Early warning signs may be detected in time for preventative healthcare to be administered.
 
Today, the market for RPM technologies and services focuses on key chronic conditions spanning cardiovascular disease, diabetes, and respiratory diseases, particularly in older adults. The world's elderly population is responsible for a large portion of healthcare spending due to the high prevalence of chronic diseases in this group, and the high cost of managing chronic diseases. Management involves high levels of care (regular check-ups and good adherence to medication regimen) over long term. With the increase in the world's elderly population predicted, even small cost reductions in this space can have drastic impacts on healthcare systems around the world.
 
This IDTechEx report focuses on the devices and technologies supporting the RPM market. The range of devices used in RPM is vast, spanning established technologies such as scales and blood pressure cuffs to growing segments such as ambulatory cardiac monitoring (e.g. mobile cardiac telemetry) and continuous glucose monitoring, to current efforts to increase the number of health metrics that can be monitored in the background on consumer wearables. Innovations in RPM technology focus on increasing patient comfort, convenience, and adherence to monitoring, while maintaining high data quality, and where relevant, providing the option of continuous monitoring. Recent activities from medical and technology giants show their interest in entering the RPM market, bringing with them much needed scale needed to support uptake. Increased reimbursement and both patient and physician comfort with the technology (due to the COVID-19 pandemic) can support the continued rise of RPM technologies.
 
In this report, IDTechEx leverages our coverage of wearable and medical technology to bring the latest in technologies, applications, and opportunities for RPM. The report takes a deep dive into a spectrum of RPM approaches in the following high impact areas:
  • Use of electronic skin patches and non-contact monitoring systems to track patients' vital signs for detection of deterioration
  • Development of cuffless blood pressure monitoring devices for management of hypertension
  • Shift towards consumer technologies in arrhythmia detection, and increasing wear time and patient comfort in mobile cardiac telemetry
  • Increasing adoption of continuous glucose monitoring technology along with efforts to closed loop insulin delivery
  • Establishment of novel digital biomarkers and adoption of RPM for decentralized clinical trials
  • Use of sensors around the home for monitoring the elderly for activities of daily living and falls
  • Potential for wearable wellness devices as an incentive for health insurance
 
Examples of technologies covered in the report include electronic skin patches, smart shirts, smartwatches, and connected inhalers. This report encompasses IDTechEx's expert analysis of wearable technology, wearable sensors, electronic textiles, electronic skin patches, and digital health, to bring to the reader the most relevant insights on the exciting innovations in RPM.
 
Key aspects
This report provides the following information:
 
  • Overview of the remote patient monitoring industry, including key companies and key industry drivers
  • Analysis of technology and trends, including key chronic disease applications
  • Increasing patient comfort and bringing continuous monitoring to hospital wards
  • Hypertension and the development of cuffless blood pressure
  • Heart rhythm and the rise of wearables
  • Diabetes and the push towards continuous glucose monitoring
  • Opportunities for wearables in movement disorders
  • Monitoring the elderly
  • Digital biomarkers and decentralized clinical trials
  • Health insurance and incentives for wearable technology
  • 10-year market forecasts for connected medical devices for remote patient monitoring of chronic conditions, spanning 19 products / product categories
IDTechEx のアナリストへのアクセス
すべてのレポート購入者には、専門のアナリストによる最大30分の電話相談が含まれています。 レポートで得られた重要な知見をお客様のビジネス課題に結びつけるお手伝いをいたします。このサービスは、レポート購入後3ヶ月以内にご利用いただく必要があります。
詳細
この調査レポートに関してのご質問は、下記担当までご連絡ください。

アイディーテックエックス株式会社 (IDTechEx日本法人)
担当: 村越美和子 m.murakoshi@idtechex.com
Table of Contents
1.EXECUTIVE SUMMARY
1.1.Scope of the Report
1.2.Factors Encouraging the Rise of Digital Health and Remote Patient Monitoring
1.3.Benefits of Remote Patient Monitoring
1.4.Components of a Remote Monitoring System
1.5.Common Measurements and Applications
1.6.Types of RPM Companies
1.7.Vital Sign Monitoring In and Out of the Hospital
1.8.RPM of Cardiovascular Diseases
1.9.RPM for Hypertension (High Blood Pressure)
1.10.RPM for Atrial Fibrillation & Other Arrythmias
1.11.RPM for Heart Failure
1.12.RPM of Diabetes and Prediabetes
1.13.RPM of Respiratory Conditions
1.14.RPM Technologies for Other Chronic Diseases
1.15.RPM in Clinical Trials
1.16.Remote Monitoring of the Elderly
1.17.Wearables for Health Insurance
1.18.Market Forecast 2023-2033: RPM Devices
2.INTRODUCTION
2.1.Scope of the Report
2.2.Factors Encouraging the Rise of Digital Health and Remote Patient Monitoring
2.3.Changing Demographics Require Healthcare Reforms
2.4.Global Healthcare Spending is Rising
2.5.Why Telemedicine?
2.6.Driving the Uptake of Telemedicine
2.7.Benefits of Remote Patient Monitoring
2.8.Components of a Remote Monitoring System
2.9.Common Measurements and Applications
2.10.The Impact of COVID-19 on Digital Health
2.11.Shifts Towards Value-Based Care
2.12.Positive Trends in Reimbursement Continues in the US
2.13.From Connected to Wearable
2.14.Broadband Access is a Determinant of Health
2.15.Design Challenges for RPM
3.REMOTE PATIENT MONITORING
3.1.Overview
3.1.1.Types of RPM Companies
3.1.2.Teladoc Health
3.1.3.Livongo by Teladoc Health
3.1.4.Amwell
3.1.5.MDLive
3.1.6.Omada Health
3.1.7.Optimize Health
3.1.8.Market Outlook
3.2.Vital Sign Monitoring - Inpatient and Outpatient
3.2.1.Introduction
3.2.2.Inpatient Monitoring: Background
3.2.3.RPM in the Hospital
3.2.4.The Case for Removing the Wires
3.2.5.RPM in the Hospital: Form Factors
3.2.6.Parameter Comparison
3.2.7.The Case Against RPM
3.2.8.Vital Sign Monitoring at Home
3.2.9.Post-Discharge Monitoring
3.2.10.COVID-19 at Home
3.2.11.Cancer
3.2.12.Cancer: Symptom Monitoring
3.2.13.Cancer: Performance Status
3.2.14.Deployment Challenges for Monitoring Devices
3.2.15.Summary and Outlook
3.2.16.Emerging Options for General Vital Sign Monitoring
3.2.17.Summary
3.2.18.Vital Sign Monitoring: Key Companies
3.2.19.Electronic Skin Patches
3.2.20.Philips
3.2.21.The Surgical Company (formerly Sensium)
3.2.22.BioIntelliSense
3.2.23.VitalConnect
3.2.24.Vivalink (VivaLNK)
3.2.25.Non-Contact Monitoring Technologies
3.2.26.EarlySense
3.2.27.EarlySense
3.2.28.Xandar Kardian
3.2.29.Oxehealth
3.3.Cardiovascular Diseases - Hypertension, Atrial Fibrillation, and Heart Failure
3.3.1.Background
3.3.2.Remote Patient Monitoring in Cardiovascular Diseases
3.3.3.Technology Summary
3.3.4.Electrocardiography (ECG, or EKG)
3.3.5.Photoplethysmography (PPG)
3.3.6.Example Charts
3.4.Hypertension
3.4.1.Background
3.4.2.Classification
3.4.3.Management
3.4.4.Remote Patient Monitoring
3.4.5.Oscillometric Method
3.4.6.Oscillometric Devices
3.4.7.Omron Healthcare
3.4.8.Omron Healthcare: HeartGuide
3.4.9.Omron Healthcare: VitalSight
3.4.10.Withings
3.4.11.Optical Measurement Techniques - Cuff-Less Blood Pressure Monitoring
3.4.12.Pulse Arrival Time, Pulse Transit Time, and Pulse Wave Velocity
3.4.13.Asus: VivoWatch BP, VivoWatch SP
3.4.14.Asus: VivoWatch SP
3.4.15.Pulse Wave Analysis
3.4.16.Pulse Wave Analysis: Methods
3.4.17.Aktiia: Aktiia Bracelet
3.4.18.Biospectal
3.4.19.Valencell: Cuffless Blood Pressure
3.4.20.Summary and Outlook
3.5.Atrial Fibrillation and Other Arrythmias
3.5.1.Background
3.5.2.(Early) Detection of Atrial Fibrillation
3.5.3.Detection and Diagnosis of Atrial Fibrillation and other Arrhythmias
3.5.4.Atrial Fibrillation: Screening & Detection
3.5.5.AliveCor
3.5.6.AliveCor: KardiaMobile
3.5.7.Qompium: FibriCheck
3.5.8.Smartwatches: Apple, Fitbit, Samsung
3.5.9.Smartwatches: User Demographics vs Cardiovascular Conditions
3.5.10.Atrial Fibrillation: Diagnosis
3.5.11.Progress Towards Ambulatory Cardiac Monitoring
3.5.12.Electronic Skin Patches
3.5.13.Electronic Skin Patches
3.5.14.Ambulatory Heart Rhythm Monitoring: Players
3.5.15.Philips (BioTelemetry)
3.5.16.iRhythm
3.5.17.Insertable Cardiac Monitors
3.5.18.Atrial Fibrillation: Treatment
3.5.19.Artificial Pacemakers
3.5.20.Artificial Pacemakers and RPM
3.5.21.Artificial Pacemakers and RPM: Platforms
3.5.22.Artificial Pacemakers and RPM: Apps
3.5.23.Summary and Outlook
3.6.Heart Failure
3.6.1.Background
3.6.2.Management and Challenges to RPM
3.6.3.Management: Lack of RPM Technologies
3.6.4.Remote Patient Monitoring
3.6.5.Management: Disease Progression
3.6.6.Abbott: CardioMEMS HF System
3.6.7.Abbott: CardioMEMS HF System
3.6.8.Non-Invasive Monitoring
3.6.9.toSense: CoVa 2
3.6.10.BodiGuide
3.6.11.Sensible Medical: ReDS for Home
3.6.12.Zoll Medical: Heart Failure Management System (HFMS), µCor
3.6.13.Chronolife: KeeSense
3.6.14.Cardiac Resynchronization Therapy with Defibrillator and Implantable Cardioverter Defibrillator
3.6.15.Summary and Outlook
3.7.Diabetes - Type 1, Type 2, and Prediabetes
3.7.1.Background
3.7.2.Delivering insulin is a critical part of diabetes management
3.7.3.Management: Self-Management Devices
3.7.4.Management: Self-Management Devices
3.7.5.Remote Patient Monitoring
3.7.6.Digital Health Programs
3.7.7.Digital Health Programs: Evidence for Type 2 Diabetes
3.7.8.Digital Health: Diabetes Apps
3.7.9.Glooko
3.7.10.Diabetes Management Ecosystem
3.7.11.Continuous Glucose Monitoring in Hospitals
3.7.12.Summary and Outlook
3.7.13.Glucose Monitoring Devices
3.7.14.Background
3.7.15.Glucose Monitoring Devices
3.7.16.Anatomy of a Glucose Test Strip
3.7.17.Continuous Glucose Monitoring (CGM)
3.7.18.Anatomy of a Typical CGM Device
3.7.19.CGM: Technology
3.7.20.CGM: Sensor Chemistry
3.7.21.CGM: Overview of key players
3.7.22.Abbott: Freestyle® Libre
3.7.23.Non-Invasive Glucose Monitoring
3.7.24.Non-Invasive Glucose Monitoring: Analytes
3.7.25.When will non-invasive glucose monitoring be commercialised?
3.7.26.Insulin Delivery Devices
3.7.27.Background
3.7.28.Insulin Delivery Devices
3.7.29.Insulin Pens
3.7.30.Insulin Pumps
3.7.31.Insulin pump players and market share
3.7.32.Hybrid Closed Loop Systems
3.7.33.Medtronic: SmartGuard Auto Mode
3.7.34.Insulin Pump Technology Roadmap
3.7.35.Closed-loop: software
3.8.Respiratory Diseases - Chronic Obstructive Pulmonary Disorder and Asthma
3.8.1.Background
3.8.2.Chronic Obstructive Pulmonary Disorder
3.8.3.Asthma
3.8.4.Remote Patient Monitoring
3.8.5.Inhalers
3.8.6.Smart Inhalers: Companies
3.8.7.Propeller Health
3.8.8.Propeller & Novartis in Asthma Care
3.8.9.Teva: Digihaler
3.8.10.BreezoMeter
3.8.11.Spirometers
3.8.12.NuvoAir
3.8.13.Other Respiratory Monitoring
3.8.14.Respiri
3.8.15.Health Care Originals
3.8.16.Spire Health
3.8.17.Summary and Outlook
3.9.Other Remote Patient Monitoring Applications
3.9.1.Other Remote Patient Monitoring Applications
3.9.2.Parkinson's Disease
3.9.3.Parkinson's Disease: The Need for More Data
3.9.4.Parkinson's Disease: Movement Sensors
3.9.5.Global Kinetics: PKG
3.9.6.Rune Labs: StrivePD
3.9.7.Rheumatoid Arthritis & Other Autoimmune Diseases
3.9.8.Multiple Sclerosis
3.9.9.Musculoskeletal Conditions
3.9.10.MSK: Digital Physical Therapy / Remote Rehabilitation
3.9.11.Zimmer Biomet: Persona IQ
3.9.12.Summary and Outlook
3.10.Remote Patient Monitoring in Clinical Trials
3.10.1.Clinical Trials
3.10.2.RPM in Clinical Trials
3.10.3.Wearables in Clinical Trials: Adoption Timeline
3.10.4.CTTI and DiMe
3.10.5.CTTI Framework of Specifications
3.10.6.Digital Endpoints
3.10.7.Digital Endpoints: Importance to Alzheimer's Disease Research
3.10.8.CTTI Database: Condition analysis
3.10.9.CTTI Database: Sensor type
3.10.10.Barriers to Adoption for Wearable RPM
3.10.11.Barriers to Adoption for Wearable RPM (con't)
3.10.12.Virtual and Decentralized Trials
3.10.13.COVID-19 Vaccine Trials
3.10.14.Sensors used in Decentralized Trials
3.10.15.Is FDA clearance necessary for success?
3.10.16.Summary and Outlook
3.11.Monitoring the Elderly
3.11.1.Background
3.11.2.Remote Monitoring Technologies for the Elderly
3.11.3.Fall Detection
3.11.4.Fall Detection: Examples
3.11.5.Fall Detection: Examples
3.11.6.Health Tracking
3.11.7.Canary Care
3.11.8.Somatix: SafeBeing
3.11.9.Diaper Monitoring
3.11.10.Technologies for Medical Adherence
3.11.11.Baby Monitoring
3.11.12.Summary and Outlook
3.12.Fitness and Wellness Wearables for Health Insurance
3.12.1.Fitness and Wellness
3.12.2.Health Insurance and Corporate Wellness
3.12.3.Vitality: Background
3.12.4.Vitality: Device Partners
3.12.5.UnitedHealth Group: Background
3.12.6.UnitedHealthcare: Target biometrics and device adoption
3.12.7.Biomarker Usage in Health Insurance: Timeline
3.12.8.Outlook for New Biomarkers?
3.12.9.Barriers to Adoption
3.12.10.Summary and Outlook
4.MARKET FORECASTS
4.1.Overview
4.2.Methodology
4.3.Market Forecast 2023-2033: RPM Devices
4.4.Market Forecast 2023-2033: General Vital Sign Monitoring
4.5.Market Forecast 2023-2033: Skin Patches for Inpatient and Outpatient Monitoring
4.6.Market Forecast 2023-2033: Non-Contact Vital Sign Monitoring Devices
4.7.Market Forecast 2023-2033: Wrist-Based Wearables
4.8.Market Forecast 2023-2033: Blood Pressure Cuffs and Home Use Pulse Oximeters
4.9.Market Forecast 2023-2033: Smart Clothing
4.10.Market Forecast 2023-2033: Skin Patches for Heart Rhythm Monitoring
4.11.Market Forecast 2023-2033: Diabetes Monitoring
4.12.Market Forecast 2023-2033: Continuous Glucose Monitors, Glucometers, and Test Strips
4.13.Market Forecast 2023-2033: Insulin Pens and Pumps
4.14.Market Forecast 2023-2033: Smart Respiratory Devices
 

価格および注文方法

遠隔患者モニタリング2023-2033年: 技術、市場、機会

£$¥
電子版_PDF(ユーザー 1-5名)
£5,650.00
電子版_PDF(ユーザー 6-10名)
£8,050.00
電子版_PDFおよびハードコピー1部(ユーザー 1-5名)
£6,450.00
電子版_PDFおよびハードコピー1部(ユーザー 6-10名)
£8,850.00
電子版_PDF(ユーザー 1-5名)
$7,000.00
電子版_PDF(ユーザー 6-10名)
$10,000.00
電子版_PDFおよびハードコピー1部(ユーザー 1-5名)
$7,975.00
電子版_PDFおよびハードコピー1部(ユーザー 6-10名)
$10,975.00
電子版_PDF(ユーザー 1-5名)
€6,400.00
電子版_PDF(ユーザー 6-10名)
€9,100.00
電子版_PDFおよびハードコピー1部(ユーザー 1-5名)
€7,310.00
電子版_PDFおよびハードコピー1部(ユーザー 6-10名)
€10,010.00
電子版_PDF(ユーザー 1-5名)
¥900,000
電子版_PDF(ユーザー 6-10名)
¥1,260,000
電子版_PDFおよびハードコピー1部(ユーザー 1-5名)
¥1,020,000
電子版_PDFおよびハードコピー1部(ユーザー 6-10名)
¥1,380,000
Click here to enquire about additional licenses.
If you are a reseller/distributor please contact us before ordering.
お問合せ、見積および請求書が必要な方はm.murakoshi@idtechex.com までご連絡ください。

レポート概要

スライド 279
フォーキャスト 2033
ISBN 9781915514196
 

コンテンツのプレビュー

pdf Document Webinar Slides
pdf Document Sample pages
 
 
 
 

Subscription Enquiry